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Abstract
Patients with inflammatory bowel disease (IBD) are at risk of sarcopenia, which is associated with poor clinical outcomes. We 
conducted this study to assess whether sarcopenia predicts the need for surgery and postoperative complications in patients 
with IBD. We performed a systematic search of four electronic databases, last updated in March, 2019. Data from studies 
comparing rates of surgery and postoperative complications in sarcopenic IBD patients versus non-sarcopenic IBD patients 
were pooled with the random-effects models. We calculated the odds ratios (OR) with a 95% confidence interval (CI). Ten 
studies with a collective total of 885 IBD patients were included in our meta-analysis. Although the analysis of raw data did 
not reveal significant differences between the two groups with respect to the rate of surgery and postoperative complications 
(OR = 1.826; 95% CI 0.913–3.654; p = 0.089 and OR = 3.265; 95% CI 0.575–18.557; p = 0.182, respectively), the analysis 
of adjusted data identified sarcopenia as an independent predictor for both of the undesirable outcomes (OR = 2.655; 95% CI 
1.121–6.336; p = 0.027 and OR = 6.097; 95% CI 1.756–21.175; p = 0.004, respectively). Thus, early detection of sarcopenia 
in patients with IBD is important to prevent undesirable outcomes.
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Introduction
The term ‘sarcopenia’ was introduced by Rosenberg in 
1997 to describe an age-related decrease in skeletal muscle 
mass [1]. According to the recent recommendation of the 
European Working Group on Sarcopenia in Older People 
(EWGSOP), sarcopenia can be diagnosed if low lean mus-
cle mass stands together with either low muscle strength 
or low physical performance [2]. In clinical practice, sar-
copenia often remains unrecognized if only body mass 
index (BMI) is used to determine nutritional status [3]. 
Several studies have shown that BMI does not predict low 
lean muscle mass accurately and the entity of sarcopenic 
obesity also exists [3–5].
Sarcopenia can be assessed anatomically and function-
ally. Anatomically, a variety of methods and measures 
are used to evaluate muscle mass, including computed 
tomography (CT), magnetic resonance imaging (MRI), 
bioelectrical impedance analysis (BIA), dual-energy X-ray 
absorptiometry (DXA) and skeletal muscle index (SMI), 
appendicular SMI (ASMI), and total psoas muscle area 
(TPA) [2]. However, there is a considerable variance in 
the cut-off thresholds for sarcopenia in these diagnostic 
modalities, while the characteristics of the (normal) refer-
ence populations also vary [6]. Functionally, the handgrip 
strength test with a standard dynamometer or a physical 
performance test such as that using the Short Physical Per-
formance Battery are the gold standards [2]. Sarcopenia 
in the elderly is often related to adverse health outcomes 
including a higher risk of hospitalization and mortality 
with associated increased healthcare costs [7, 8]. Recently, 
sarcopenia was implicated as a prognostic factor in a wide 
range of diseases, such as cancer [9, 10], chronic liver dis-
eases [11], chronic pancreatitis [12], rheumatic diseases 
[13] and inflammatory bowel disease (IBD) [14].
Crohn’s disease (CD) and ulcerative colitis (UC) are 
the two main forms of IBD, and both are characterized by 
chronic inflammation of the digestive tract. Bryant et al. 
reported low lean muscle mass and sarcopenia in 21% and 
12% of adult IBD patients, respectively [3]. In a recent 
systematic review, the incidence of sarcopenia was as high 
as 52% in CD and 37% in UC, when anatomical criteria 
were considered without functional strength assessment 
[14]. Undesired consequences of the altered body compo-
sition in IBD include bone demineralization (osteopenia 
and osteoporosis), inadequate response to therapy, and 
poor quality of life [3, 15]. Despite the associations sup-
porting the adverse effect of sarcopenia in many diseases 
other than IBD, there have been only a few low-volume 
trials addressing this problem. Thus, we performed this 
meta-analysis to summarize and synthesize the results of 
the most up-to-date literature investigating the effect of 
sarcopenia, as a prognostic factor, on the need for disease-
related surgery and on the characteristics of postoperative 
complications in patients with IBD.
Methods
This meta-analysis was reported in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement (Supplementary Table 1) 
[16]. The protocol was registered in the International Pro-
spective Register of Systematic Reviews (PROSPERO) a 
priori under registration number CRD42018118517.
Data sources and search strategy
Our search was conducted in four electronic databases using 
PubMed (http://www.ncbi.nlm.nih.gov/pubme d), EMBASE 
(https ://www.embas e.com), Central Cochrane Register of 
Controlled Trials (CENTRAL) (http://www.cochr aneli 
brary .com) and Web of Science (www.webof knowl edge.
com), last updated 13 March 2019. ‘English-language’ and 
‘human’ filters were applied to the search. A manual search 
was also done by browsing the reference lists of relevant 
papers and review articles to identify additional studies. The 
PECO items of our prognostic meta-analysis were as fol-
lows: (P) adult patients with IBD, with available body com-
position assessment results; (E) those who had diagnosed 
sarcopenia; and (C) those who did not have sarcopenia. Our 
outcomes (O) included the number of surgical interventions 
and postoperative complications. The standardized Clavien-
Dindo classification tool was applied to categorize minor 
and major postoperative complications [17]. Major compli-
cations were defined as grade ≥ III on the Clavien-Dindo 
scale. Studies were identified by entering (‘body composi-
tion’ OR sarcopenia) AND (inflammatory bowel disease or 
Crohn or ‘ ulcerative colitis’) combining Medical Subject 
Headings (MeSH) and free-text terms.
Study selection
After importing all references into a reference management 
software (EndNote X8, Clarivate Analytics, Philadelphia, 
PA, US), duplicates and database overlaps were removed by 
one of the authors (AE). To maximize the precision of selec-
tion, the remaining records were screened based on title and 
abstract, independently, by two of the authors (AE and PS). 
Finally, the same two authors verified whether the remaining 
full-text articles or abstracts truly fit the inclusion criteria. 
If there was disagreement at any stage of the selection, the 
opinion of a third author (PH) was sought to reach a con-
sensus. English-language full-text articles and conference 
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proceedings were eligible for inclusion if they met our inclu-
sion criteria. Uncontrolled studies were excluded.
Data extraction and quality assessment
From the included studies, two authors extracted the data 
according to a predefined data abstraction form: first author, 
year and form of publication (full-text article/abstract only), 
study design, sample size, and outcome (rate of patients 
requiring IBD-related surgery and postoperative complica-
tions). The definition of sarcopenia and the type of surgery 
were also recorded (Table 1). Adjusted results generated 
from, and covariates imputed in, multivariate logistic regres-
sion models were also collected (Supplementary Table 2).
We also collected data on patient characteristics such 
as age, sex, disease duration, BMI, smoking, prior use of 
immunomodulatory or biological therapies, and preopera-
tively measured laboratory parameters including hemoglobin 
(Hb), serum albumin level, C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR) (Table 2). Two inde-
pendent investigators (AE and PS) performed the quality 
assessment separately and any disagreements were resolved 
by discussion. A critical appraisal tool for prognostic stud-
ies, the Quality in Prognosis Studies (QUIPS), was used to 
assess the methodological quality of the studies included 
[18]. QUIPS covers six main domains, namely, study par-
ticipation, study attrition, prognostic factor and outcome 
measurement, study confounding and statistical analysis, and 
reporting. For each item of the six domains, we used ‘yes’, 
‘no’, or ‘unclear’ to assess the risk of bias. Each domain was 
then judged as carrying ‘low’, ‘moderate’ or ‘high’ risk of 
bias (Supplementary Table 3).
Statistical analysis
The Comprehensive MetaAnalysis software Version 3 (Bio-
stat, Inc., Englewood, NJ, USA) was applied to perform 
meta-analytical calculations with the random effects model 
[19]. We computed relative measures [odds ratios (ORs) 
and weighted mean differences (WMDs)] and event rates 
with 95% confidence intervals (CIs). The main outcomes, 
namely, surgical interventions and postoperative complica-
tions, were handled as binary variables. First, ORs from raw 
2 × 2 contingency tables were pooled [19]. Peto’s OR was 
calculated in the case of the study of Carvalho et al. due to 
rare events [20]. In addition, covariate-adjusted ORs com-
puted with multivariable logistic regression models in the 
individual studies were pooled [19]. For numerical variables, 
namely, age, disease duration, BMI, and laboratory param-
eters, WMDs were calculated. For differences regarding sex, 
smoking, prior immunomodulator and biologics use between 
groups, event rates were calculated.
The results of our statistical analysis are shown in tables 
and forest plots. All analyses were two-tailed and p < 0.05 
was considered significant. For assessing heterogeneity, 
Cochrane’s Q and the I2 statistics were used. In the case 
of the Q statistic, Q exceeds the upper-tail critical value of 
Chi-square with the k − 1 degree of freedom. I2 represents 
the percentage of effect size heterogeneity, which cannot be 
explained by random chance. Based on the cochrane hand-
book for systematic reviews of interventions, heterogeneity 
was interpreted as moderate if it was between 30 and 60%, 
as substantial if it was between 50 and 90%, and as consider-
able if it was above 75% [20]. Publication bias was assessed 
by the visual inspection of the funnel plot, which was com-
plemented with the Egger’s test for analysis of the need for 
surgical interventions [20].
Results
Search results
A total of 1260 records were identified from the databases 
with our systematic search (PubMed: 283; EMBASE: 418; 
CENTRAL: 39 and Web of Science: 520 articles) (PRISMA 
flowchart; Fig. 1). Other two potentially eligible articles 
were identified by our manual search [21, 22]. After remov-
ing all duplicates, 735 records remained, 709 of which were 
excluded based on title and abstract screening. According 
to our selection criteria, 26 potentially eligible full-text arti-
cles and abstracts were considered for final inclusion, 16 of 
which were excluded, because they (1) failed to report the 
outcomes of interest (n = 11), (2) were systematic reviews 
(n = 3), or (3) were published only in abstract form not con-
taining the required data (n = 2). Ten studies were included 
in the final quantitative analysis [21–30].
Characteristics of the studies included
Table 1 summarizes the characteristics of the included stud-
ies. The trials were published between 2015 and 2018 and 
all studies were published in full-text form, except for one 
released as an abstract [28]. The majority were case–control 
studies and only two prospective cohort studies of Zhang 
et al. were eligible for meta-analysis [29, 30]. In four studies, 
patients with CD were recruited [21, 25, 28, 30], whereas in 
another three studies, only patients with UC were recruited 
[26, 27, 29]. In three trials, a mixed cohort of patients with 
CD and UC were recruited [22–24].
To quantify the degree of sarcopenia, the majority of 
studies measured the SMI at the level of the third lumbar 
vertebra on CT scan, performed within 6 months prior to 
surgery or in the first postoperative month. The cut-off val-
ues of the SMI defining sarcopenia ranged between 39 and 
1141Surgery Today (2020) 50:1138–1150 
1 3
Table 1  Study characteristics and measured outcomes
Author (year) 
study type
Number of 
patients (CD/
UC)
Definition of sarco-
penia
Type of 
surgery
Number of 
patients in 
the study 
groups (n)
Outcomes (number of patients)
Surgery Postopera-
tive compli-
cation
Minor 
postoperative 
complication
Major 
postoperative 
complication
Adams [23] 
retrosp.
90 (76/14) Men: 
SMI < 52.4 cm2/m2
Women: 
SMI < 38.5 cm2/m2
Previous 
surgery, not 
specified
Sarcopenic 
(41)
21 NA NA NA
Non-sarco-
penic (49)
19 NA NA NA
Bamba [24] 
retrosp.
72 (43/29) Men: SMI < 42 cm2/
m2
Women: 
SMI < 38 cm2/m2
Intestinal 
resection, 
not speci-
fied
Sarcopenic 
(30)
16 NA NA NA
Non-sarco-
penic (42)
9 NA NA NA
Carvalho [25] 
retrosp.
58 (58/0) Men: SMI < 52.4 
cm2/m2 Women: 
SMI < 38.5  cm2/m2
Surgical 
resection, 
not speci-
fied
Sarcopenic 
(24)
7 7 NA NA
Non-sarco-
penic (34)
17 2
Cushing [26] 
retrosp.
82 (0/82) Men: SMI < 55 cm2/
m2
Women: 
SMI < 39 cm2/m2
Colectomy Sarcopenic 
(57)
16 NA NA NA
Non-sarco-
penic (25)
3 NA NA NA
Fujikawa [27] 
retrosp.
69 (0/69) Men: 
TPA < 567.4 mm2/
m2
Women: 
TPA < 355.8 mm2/
m2
Two- or 
three-
stage ileal 
J-pouch–
anal anas-
tomosis 
(IPPA)
Sarcopenic 
(18)
NA 8 4 4
Non-sarco-
penic (51)
NA 5 3 2
O’Brien [22] 
retrosp
77 (52/21)b In case of 
BMI < 25 kg/m2:
men: SMI < 43 cm2/
m2
women: 
SMI < 41 cm2/m2;
In case of 
BMI ≥ 25 kg/m2:
men: SMI < 53 cm2/
m2
IPPA, 
ileocecec-
tomy, hemi-
colectomy, 
colectomy, 
panprocto-
colectomy 
with or 
without 
ileostomy 
formation
Sarcopenic 
(30)
77 6 NA 6
Non-sarco-
penic (47)
10 10
Oh [28] 
retrosp.
79 (79/0) Men: SMI < 55 cm2/
m2
Women: 
SMI < 39 cm2/m2
Surgery, not 
specified
Sarcopenic 
(64)
11 NA NA NA
Non-sarco-
penic (15)
2 NA NA NA
Thiberge [21] 
retrosp.
149 (149/0) Men: 
SMI < 55.4 cm2/m2
Men: 
SMI < 38.9 cm2/m2
Stric-
turoplasty, 
bowel 
resection, 
stoma 
without 
resection, 
perianal/
abdominal 
abscess 
drainage, 
viscerolysis
Sarcopenic 
(50)
OR: 2.03a, 
(CI 
0.98–4.26), 
p = 0.056
NA NA NA
Non-sarco-
penic (99)
NA NA NA
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41 cm2/m2 for women and between 52 and 55 cm2/m2 for 
men. Bamba et al. used standardized SMI cut-off values for 
liver disease with a lower SMI for men (42 cm2/m2) [24]. 
Only one study applied TPA for sarcopenia assessment [27].
Whilst seven studies compared IBD patients with sarco-
penia versus those without sarcopenia in relation to need 
for surgery [21, 23–26, 28, 29], only four studies pub-
lished results on complications occurring in the first month 
after surgery [22, 25, 27, 30]. A total of 275 IBD-related 
operations were performed in the studies included. A high 
diversity of surgical interventions was registered, includ-
ing stricturoplasty, bowel resection, abscess drainage, vis-
cerolysis, ileal J-pouch–anal anastomosis, and various types 
of colectomy.
Patients’ characteristics
Altogether, 885 patients with IBD were included in this 
meta-analysis: 571 (64.5%) with CD and 314 (35.5%) with 
UC. Based on the body composition measurements, 46.2% 
(409/885) of the patients had sarcopenia. There were signifi-
cantly more men in the sarcopenic group than in the non-
sarcopenic group (66.8% vs. 46.3%, p = 0.027; Tables 2 and 
3). Patients with IBD and sarcopenia had significantly lower 
BMI and preoperative serum albumin levels and significantly 
higher CRP levels than the non-sarcopenic patients (WMD: 
2.698 kg/m2, 95% CI 1.507–3.889, p < 0.001; I2 = 52.39%, 
p = 0.078; WMD: 3.276  g/dL, 95% CI 0.022–0.623, 
p = 0.035; I2 = 90.74%, p < 0.001 and WMD: 12.740 mg/L, 
95% CI 7.154–18.326, p < 0.001; I2= 0%, p = 0.524, respec-
tively). There were no significant differences in age, disease 
duration, smoking habits, or prior immunomodulator or 
biologics use between the sarcopenic and the non-sarcopenic 
groups (Table 3).
Analyzing preoperative laboratory studies (serum albu-
min and CRP) and other patient characteristics (such as 
the rate of sarcopenia, BMI, SMI, and height) by IBD sub-
types revealed that the rate of sarcopenia was significantly 
higher in patients with CD than in those with UC (60.7% vs. 
36.7%, p = 0.044) [24, 29]. The preoperative serum albumin 
level was also significantly higher in those with CD than in 
those with UC (WMD: 0.337 g/dL, 95% CI 0.055–0.619, 
p = 0.019; I2 = 67.53%, p = 0.079) (Supplementary Table 4) 
[24, 29].
Need for surgery
Seven studies assessed the need for surgical intervention 
in IBD patients with versus those without sarcopenia [21, 
23–26, 28, 29]. Overall, 35.5% (104/293) of the sarcopenic 
and 27.9% (94/336) of the non-sarcopenic patients under-
went disease-related surgery, respectively. The raw data on 
the number of sarcopenic and non-sarcopenic patients with 
IBD who underwent surgery were available in six studies 
[23–26, 28, 29]. Analysis of the unadjusted data showed no 
significant difference between the two groups with respect 
to the need for surgical interventions (unadjusted OR: 1.826; 
95% CI 0.913–3.654; p = 0.089). Moderate heterogeneity 
was detected across the studies (I2 = 54.62%, p = 0.051) 
(Fig. 2). Three studies were adjusted for significant covari-
ates [21, 26, 29]. After pooling the adjusted ORs together, 
sarcopenia proved to be an independent predictor of the 
need for surgery (adjusted OR: 2.665; 95% CI 1.121–6.336; 
p = 0.027), with moderate between-study heterogeneity 
(I2 = 33.94%, p = 0.220) (Fig. 3).
CD crohn’s disease, UC ulcerative colitis, SMI skeletal muscle index, TPA total psoas muscle area, OR odds ratio, CI confidence interval, p p 
value, retrosp retrospective, prosp prospective, NA non-available
a No raw data available
b Additional four cases of indeterminate colitis
Table 1  (continued)
Author (year) 
study type
Number of 
patients (CD/
UC)
Definition of sarco-
penia
Type of 
surgery
Number of 
patients in 
the study 
groups (n)
Outcomes (number of patients)
Surgery Postopera-
tive compli-
cation
Minor 
postoperative 
complication
Major 
postoperative 
complication
Zhang [29] 
prosp.
114 (114/0) Men: SMI < 55 cm2/
m2
Women: 
SMI < 39 cm2/m2
Segmen-
tal/total 
colectomy, 
ileocecal/
small bowel 
resection
Sarcopenic 
(70)
NA 32 21 11
Non-sarco-
penic (44)
NA 26 25 1
Zhang [30] 
prosp.
99 (0/99) Men: SMI < 55 cm2/
m2
Women: 
SMI < 39 cm2/m2
Colectomy Sarcopenic 
(27)
7 NA NA NA
Non-sarco-
penic (72)
7 NA NA NA
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When the data of the CD and UC patients were analyzed 
separately, no significant difference was found between the 
sarcopenic and non-sarcopenic groups in the rate of surgical 
intervention (unadjusted OR: 1.566; 95% CI 0.415–5.904; 
p = 0.508; I2 = 81.65%, p = 0.004 and unadjusted OR: 2.931; 
95% CI 0.760–11.309; p = 0.119; I2 = 0.0%, p = 0.978, 
respectively) (Fig. 4).
Postoperative complications
Four studies were eligible for analysis of postoperative 
complications in IBD patients with versus those without 
sarcopenia [22, 25, 27, 30] (Fig. 5a). Postoperative com-
plications developed in 37.3% (53/142) of the sarcopenic 
patients versus 24.4% (43/176) of the non-sarcopenic group, 
without a significant difference between the two groups 
(unadjusted OR: 3.265; 95% CI 0.575–18.557; p = 0.182; 
I2 = 88.46%, p < 0.001). Two studies were adjusted for sig-
nificant covariates [27, 30]. After pooling the adjusted ORs 
together, sarcopenia proved to be an independent predictor 
of postoperative complications (adjusted OR = 6.097; 95% 
CI 1.756–21.175; p = 0.004), with negligible between-study 
heterogeneity (I2 = 0.0%, p = 0.637) (Fig. 6).
Performing subgroup analysis based on the Clavien-
Dindo grading system, sarcopenia was not a risk factor of 
minor or major postoperative complications (unadjusted OR: 
1.107; 95% CI: 0.084-14.632; p = 0.939, and unadjusted 
OR: 3.124; 95% CI: 0.666-14.652; p = 0.149, respectively) 
(Fig. 5b, c). Considerable heterogeneity was observed in the 
analyses of overall, minor, and major postoperative compli-
cations (I2 = 88.46%, p < 0.001; I2 = 88.01%, p = 0.004; and 
I2 = 62.31%, p = 0.070, respectively).
Risk of bias assessment
Supplementary Figs. 1 and 2 summarize the results of the 
risk of bias assessment of the individual studies and Sup-
plementary Fig.  3 shows the adapted QUIPS tool. The 
Fig. 1  Flow diagram of the 
study selection process
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main domain ‘study attrition’ and further selected items 
not suitable for the studies included in the meta-analysis 
were omitted. Based on our analysis, the study of Thiberge 
et al. obtained the best scores with only one moderate risk 
of bias, while the study of Oh showed the worst results with 
two domains classified as carrying high and one domain 
classified as carrying a moderate risk of bias. All the stud-
ies included were assessed as carrying a high risk of bias 
in at least one domain. The domain of ‘prognostic factor 
measurement’ was the best rated, as all the included studies 
Table 3  Heterogeneity of data on the differences in patient characteristics and laboratory parameters of the sarcopenic and non-sarcopenic study 
groups
BMI body mass index, Hg hemoglobin, CRP C-reactive protein, ESR erythrocyte sedimentation rate, CI confidence interval, df degree of free-
dom
Associations significant at p < 0.05 vs controls shown in bold
Difference 
in means
95% CI p value Heterogeneity
Lower limit Upper limit Q value df (Q) p value I2
Age − 1.432 − 7.215 4.351 0.627 14.260 4 0.007 71.95
Disease duration (months) − 1.441 − 5.403 2.522 0.476 0.861 2 0.650 0.0
BMI − 2.698 − 3.889 − 1.507 < 0.001 8.401 4 0.078 52.39
Preoperative Hb − 3.437 − 9.502 2.951 0.302 0.730 1 0.393 0.0
Preoperative serum albumin − 3.276 − 0.623 − 0.022 0.035 53.97 5 0.000 90.74
Preoperative CRP 12.740 7.154 18.326 < 0.001 3.204 4 0.524 0.0
Preoperative ESR 3.163 − 8.137 14.463 0.583 1.407 1 0.236 28.94
Event rate 95% CI p value Heterogeneity
Lower limit Upper limit Q value df (Q) p value I2
Sex, male: sarcopenic 0.668 0.541 0.775 0.027 11.247 5 0.047 55.44
Sex, male: non-sarcopenic 0.463 0.338 0.593 25.723 5 0.000 80.56
Smoking: sarcopenic 0.146 0.081 0.247 0.786 8.326 2 0.016 75.99
Smoking: non-sarcopenic 0.137 0.056 0.286 2.426 2 0.297 17.55
Prior immunomodulators: sarcopenic 0.593 0.411 0.752 0.400 7.544 2 0.023 73.45
Prior immunomodulators: non-sarcopenic 0.484 0.316 0.657 6.403 2 0.041 68.77
Prior biologics: sarcopenic 0.354 0.260 0.461 0.815 10.769 1 0.005 81.43
Prior biologics: non-sarcopenic 0.341 0.258 0.434 15.742 2 0.000 87.23
Fig. 2  Forest plot of studies evaluating inflammatory bowel disease 
(IBD)-related surgical interventions in the sarcopenic and non-sarco-
penic study groups (unadjusted results). Size of squares for the odds 
ratio reflects the weight of the trial in pooled analyses. Horizontal 
bars represent 95% confidence intervals
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were judged to carry a low risk of bias. In contrast, 90% of 
the studies showed a high risk of bias in the term of ‘study 
confounding’, since they did not report how the important 
confounders were adjusted for and whether an appropriate 
method was used for handling missing data. In all the studies 
evaluated, ‘study participation’ and ‘outcome measurement’ 
domains carried low or moderate risk of bias. Most of the 
studies (90%) detailed statistical analysis properly and were, 
therefore, awarded a green notation in this regard.
Publication bias
Based on visual assessment of the funnel plot (symmetric) 
and the Egger’s test result (p = 0.91), a ‘small-study effect’ 
is unlikely to occur in the analysis of the need for surgical 
intervention (Supplementary Fig. 3).
Discussion
Sarcopenia is relevant for patients with IBD as it can lead 
to poor outcomes, such as bone demineralization with con-
sequential pathological fractures, hospitalization, reduced 
mobility, and compromised quality of life [31]. Apart from 
the increased level of pro-inflammatory mediators, inad-
equate calorie intake, malabsorption, and protein-losing 
enteropathy, different pharmacological and surgical treat-
ments may also impair nutritional status in IBD [15]. 
Fig. 3  Forest plot of studies evaluating IBD-related surgical interventions in the sarcopenic and non-sarcopenic study groups (adjusted results). 
Size of squares for the odds ratio reflects the weight of the trial in pooled analyses. Horizontal bars represent 95% confidence intervals
Fig. 4  Forest plots of studies evaluating the effect of sarcopenia on 
disease-related surgical interventions in the Crohn’s disease (CD) and 
ulcerative colitis (UC) patient populations (unadjusted results). Size 
of squares for odds ratio reflects weight of trial in pooled analysis. 
Horizontal bars represent 95% confidence intervals. UC ulcerative 
colitis, CD Crohn’s disease
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Fig. 5  Forest plot of studies evaluating postoperative complications 
in the sarcopenic and non-sarcopenic patients with IBD (unadjusted 
results). a All complications; b minor complications were defined as 
grade I–II; c major complications were defined as grade ≥ III on the 
Clavien-Dindo scale. Size of squares for the odds ratio reflects the 
weight of the trial in pooled analyses. Horizontal bars represent 95% 
confidence intervals
Fig. 6  Forest plot of studies evaluating postoperative complications 
in the sarcopenic and non-sarcopenic patients with IBD considering 
all complications (adjusted results). Size of squares for the odds ratio 
reflects the weight of the trial in pooled analyses. Horizontal bars rep-
resent 95% confidence intervals
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However, few studies have evaluated the effect of sarcopenia 
as a prognostic factor of surgical outcomes.
Our meta-analysis found only seven studies with con-
troversial results on surgical interventions for sarcopenic 
patients with IBD. Although we did not detect a significant 
difference between the rate of surgical interventions for 
the sarcopenic patients versus the non-sarcopenic patients 
with IBD when unadjusted data were pooled, our analysis 
of covariate-adjusted data identified sarcopenia as an inde-
pendent predictor of surgical interventions in patients with 
IBD. A potential explanation for this phenomenon could be 
the effect of bias (especially selection bias), which masked 
the true difference in the unadjusted analysis (Figs. 2 and 
5), but was reduced, at least partly, with the introduction of 
multivariate models (Figs. 3 and 6). Regarding IBD subtype 
(CD or UC), no significant difference was observed in surgi-
cal interventions, although there was a trend towards a more 
frequent need for surgery in sarcopenic patients with UC.
Similarly, we could only detect significant differences 
between the groups with respect to postoperative compli-
cations when adjusted data were analyzed. This finding is 
consistent with previous meta-analyses on patients who 
underwent oncological abdominal surgery, where radiologi-
cally proven sarcopenia was associated with a significant 
increase in major postoperative complications as well as in 
30-day mortality [32, 33]. In our meta-analysis, most of the 
sarcopenic patients were men. Interestingly, a previous study 
identified sarcopenia as a predictor of a subsequent surgery 
only in women with IBD [34]. Other clinical features such as 
age, disease duration, smoking, and prior therapies did not 
differ considerably between the groups. We also found lower 
BMI and serum albumin levels and higher CRP levels in the 
sarcopenic group. It should be noted that measuring these 
parameters can be helpful in the prediction of sarcopenia. 
Since cross-sectional imaging is frequently ordered preop-
eratively, the results of CT or MRI scans would provide a 
more accurate estimation of lean muscle mass.
Although the consequences of malnutrition, such as poor 
bone health, delayed puberty and growth failure, are more 
prevalent in pediatric patients with IBD, our meta-analysis 
highlighted that the assessment of body composition is also 
necessary in adult patients with IBD [35]. The importance 
of evaluating the nutritional status of an IBD patient was 
emphasized in the recent European Crohn’s and Colitis 
Organisation (ECCO) guidelines [36, 37]. Malnutrition and 
hypalbuminaemia are listed as the main risk factors of post-
operative complications, including anastomotic leak, peri-
tonitis, and intra-abdominal septic complications [36]. Prior 
to surgery, not only the responsible adjustment of medical 
therapy, such as weaning off steroid treatment if possible, 
but also preoperative enteral or parenteral nutritional support 
may help to reduce the risk of surgical and postoperative 
complications [38–42].
Several limitations of this meta-analysis must be con-
sidered. First, the vast majority of included studies were 
retrospective with a small sample size and a wide variety 
of surgical interventions, raising concerns about impreci-
sion and indirectness. Second, none of the included studies 
used EWGSOP criteria to assess functional loss of muscle 
strength measurement. Third, only one study assessed the 
effect of nutritional therapy, in which preoperative enteral 
nutrition was a protective factor against major postopera-
tive complications [30]. Furthermore, minor differences 
were observed with respect to the covariates imputed in 
the logistic regression models, which may affect our results 
(Supplementary Table 2). As heterogeneity tests indicated 
homogeneous datasets (Figs. 3 and 6), we do not suspect 
rough distortion. Finally, there was considerable heterogene-
ity in cut-off points for the sarcopenia definition regarding 
ethnicity, carrying the potential of under- or overestimating 
the sarcopenia rate in the included studies.
The main strength of our work is its novelty, but we must 
mention the foremost systematic review by Ryan et al. [14] 
investigating the prognostic role of sarcopenia in the out-
comes of surgery for IBD. Our review revealed the need for 
longitudinal observational studies in this field. The highly 
transparent and reproducible methodology of this work was 
ensured by strictly adhering to the rules and recommenda-
tions of the PRISMA guidelines.
In conclusion, the findings of our analysis have implica-
tions for practice, particularly in the promotion of preop-
erative individualized risk prediction. In addition to simple 
anthropometric tests, anatomical and functional measure-
ments should be performed. The SMI, measured on a CT 
scan, can be used as an objective assessment tool to identify 
sarcopenia in patients with IBD. To interpret the body com-
position and nutritional status of patients with IBD, a multi-
disciplinary approach is recommended. Education on nutri-
tional issues is best provided by well-trained dietitians with 
a special interest in IBD. Since sarcopenia may be reversible 
with adequate nutritional support, targeted preoperative risk 
reduction strategies are recommended to optimize surgical 
outcomes. Further research through large prospective cohort 
studies is needed to confirm our findings and conclusions.
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